Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19853446 | 0.76 | — | — | |
| SCHEMBL20072398 | 0.76 | CCR1 (0.46) | RAB9A | |
| SCHEMBL13547890 | 0.76 | ESR1 (0.40) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL2604908 | 0.75 | ESR1 (0.42) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL15831685 | 0.73 | ESR1 (0.41) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL5102670 | 0.73 | ESR1 (0.44) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL14241223 | 0.73 | ESR1 (0.49) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL20802535 | 0.73 | ESR1 (0.41) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL4369960 | 0.73 | ESR1 (0.41) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL22768844 | 0.73 | ESR1 (0.41) | ESR1ESR2NPC1RAB9APRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180036308-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036308-A1 | NOVEL COMPOUNDS | CYFIP1, CYFIP2, ZFX | ESR1 4828/4885ESR2 4381/4885MEN1 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.